Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Geron ( (GERN) ) is now available.
On December 16, 2025, Geron Corporation began implementing a strategic restructuring plan to enhance financial discipline and long-term value creation. This plan includes reducing its workforce by approximately one-third, impacting around 260 employees, with expected completion in the first quarter of 2026. The restructuring is anticipated to incur charges of about $18 million, primarily for employee severance and related costs, affecting financial results in late 2025 and early 2026.
The most recent analyst rating on (GERN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Geron stock, see the GERN Stock Forecast page.
Spark’s Take on GERN Stock
According to Spark, TipRanks’ AI Analyst, GERN is a Neutral.
Geron’s stock score is primarily impacted by its financial performance challenges, including profitability and cash flow issues. Technical analysis shows positive momentum, but valuation concerns due to negative earnings weigh heavily. The earnings call provided mixed insights, with some positive developments overshadowed by demand challenges.
To see Spark’s full report on GERN stock, click here.
More about Geron
Geron Corporation operates in the biotechnology industry, focusing on developing innovative therapeutics for patients. The company aims to create long-term value for both patients and shareholders.
Average Trading Volume: 7,852,017
Technical Sentiment Signal: Sell
Current Market Cap: $868.2M
Learn more about GERN stock on TipRanks’ Stock Analysis page.